Seoul Office Will Be Opening to Develop Immunomic Therapeutics Investigational Cell Therapy for Brain Cancer
September 10, 2020 08:00 AM Eastern Daylight Time SEOUL–(BUSINESS WIRE)–Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, originating in the United States recently opened its first office in South Korea. This continues to build on ITI’s overall strategy to be the partner-of-choice for innovative biotechnology companies in emerging centers of excellence worldwide.